PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors.

导出 OA

翻译打印收藏纠错

第一作者： Elizabeth S,Higgs

第一单位： Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.

作者： Elizabeth S,Higgs ^[1] ; Dehkontee,Gayedyu-Dennis ^[2] ; William A,Fischer Ii ^[3] ; Martha,Nason ^[4] ; Cavan,Reilly ^[1] ; Abdoul Habib,Beavogui ^[5] ; Jamila,Aboulhab ^[6] ; Jacqueline,Nordwall ^[7] ; Princess,Lobbo ^[1] ; Ian,Wachekwa ^[5] ; Huyen,Cao ^[2] ; Tomas,Cihlar ^[8] ; Lisa,Hensley ^[9] ; H Clifford,Lane ^[9]

作者单位： Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA. ^[1] Duport Road Clinic, Paynesville, Liberia Partnership for Research on Ebola Virus in Liberia, Monrovia, Liberia. ^[2] Division of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, North Carolina, USA. ^[3] USA Institute of Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA. ^[4] Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA. ^[5] Centre National de Formation et de Recherche en Santé Rurale de Maferinyah, Forecariah, Guinea. ^[6] Bioclinical and Fundamental Sciences Chair, Department of Medical Sciences, Faculty of Health Science and Techniques, Gamal Abdel Nasser University of Conakry, Conakry, Guinea. ^[7] John F. Kennedy Medical Center, Monrovia, Liberia. ^[8] Gilead Sciences, Foster City, California, USA. ^[9]

关键词 Ebola survivors Ebola virus disease controlled clinical trial post-Ebola syndrome remdesivir